SM Moghimi
SM Moghimi
Professor of Pharmaceutics and Nanomedicine; School of Pharmacy and Institute of Cellular Medicine
Verified email at ncl.ac.uk
Title
Cited by
Cited by
Year
Long-circulating and target-specific nanoparticles: theory to practice
SM Moghimi, AC Hunter, JC Murray
Pharmacological reviews 53 (2), 283-318, 2001
42152001
Nanomedicine: current status and future prospects
SM Moghimi, AC Hunter, JC Murray
The FASEB journal 19 (3), 311-330, 2005
22982005
Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties
SM Moghimi, J Szebeni
Progress in lipid research 42 (6), 463-478, 2003
13772003
A two-stage poly (ethylenimine)-mediated cytotoxicity: implications for gene transfer/therapy
SM Moghimi, P Symonds, JC Murray, AC Hunter, G Debska, A Szewczyk
Molecular therapy 11 (6), 990-995, 2005
10712005
The possible “proton sponge” effect of polyethylenimine (PEI) does not include change in lysosomal pH
RV Benjaminsen, MA Mattebjerg, JR Henriksen, SM Moghimi, ...
Molecular Therapy 21 (1), 149-157, 2013
5832013
Factors controlling nanoparticle pharmacokinetics: an integrated analysis and perspective
SM Moghimi, AC Hunter, TL Andresen
Annual review of pharmacology and toxicology 52, 481-503, 2012
4622012
Poloxamers and poloxamines in nanoparticle engineering and experimental medicine
SM Moghimi, AC Hunter
Trends in biotechnology 18 (10), 412-420, 2000
4512000
Non-phagocytic uptake of intravenously injected microspheres in rat spleen: influence of particle size and hydrophilic coating
SM Moghimi, CJH Porter, IS Muir, L Illum, SS Davis
Biochemical and biophysical research communications 177 (2), 861-866, 1991
3271991
Coating particles with a block co-polymer (poloxamine-908) suppresses opsonization but permits the activity of dysopsonins in the serum
SM Moghimi, IS Muir, L Illum, SS Davis, V Kolb-Bachofen
Biochimica et Biophysica Acta (BBA)-Molecular Cell Research 1179 (2), 157-165, 1993
3031993
Nanotechnologies for Alzheimer's disease: diagnosis, therapy, and safety issues
D Brambilla, B Le Droumaguet, J Nicolas, SH Hashemi, LP Wu, ...
Nanomedicine: Nanotechnology, Biology and Medicine 7 (5), 521-540, 2011
2852011
Serum-mediated recognition of liposomes by phagocytic cells of the reticuloendothelial system–the concept of tissue specificity
SM Moghimi, HM Patel
Advanced drug delivery reviews 32 (1-2), 45-60, 1998
2791998
Complement proteins bind to nanoparticle protein corona and undergo dynamic exchange in vivo
F Chen, G Wang, JI Griffin, B Brenneman, NK Banda, VM Holers, ...
Nature nanotechnology 12 (4), 387-393, 2017
2742017
Distinct polymer architecture mediates switching of complement activation pathways at the nanosphere− serum interface: implications for stealth nanoparticle engineering
I Hamad, O Al-Hanbali, AC Hunter, KJ Rutt, TL Andresen, SM Moghimi
ACS nano 4 (11), 6629-6638, 2010
2532010
Poly (ethylene glycol) s generate complement activation products in human serum through increased alternative pathway turnover and a MASP-2-dependent process
I Hamad, AC Hunter, J Szebeni, SM Moghimi
Molecular immunology 46 (2), 225-232, 2008
2332008
Material properties in complement activation
SM Moghimi, AJ Andersen, D Ahmadvand, PP Wibroe, TL Andresen, ...
Advanced drug delivery reviews 63 (12), 1000-1007, 2011
2302011
The polyoxyethylene/polyoxypropylene block co-polymer poloxamer-407 selectively redirects intravenously injected microspheres to sinusoidal endothelial cells of rabbit bone marrow
CJH Porter, SM Moghimi, L Illum, SS Davis
FEBS letters 305 (1), 62-66, 1992
2191992
Polycation cytotoxicity: a delicate matter for nucleic acid therapy—focus on polyethylenimine
L Parhamifar, AK Larsen, AC Hunter, TL Andresen, SM Moghimi
Soft Matter 6 (17), 4001-4009, 2010
2072010
Methylation of the phosphate oxygen moiety of phospholipid‐methoxy (polyethylene glycol) conjugate prevents PEGylated liposome‐mediated complement activation and anaphylatoxin …
S Moein Moghimi, I Hamad, TL Andresen, K Jørgensen, J Szebeni, ...
The FASEB journal 20 (14), 2591-2593, 2006
2042006
Capture of stealth nanoparticles by the body’s defences
SM Moghimi, C Hunter
Critical Reviews™ in Therapeutic Drug Carrier Systems 18 (6), 2001
1922001
Mechanisms and barriers in cancer nanomedicine: addressing challenges, looking for solutions
TJ Anchordoquy, Y Barenholz, D Boraschi, M Chorny, P Decuzzi, ...
ACS nano 11 (1), 12-18, 2017
1912017
The system can't perform the operation now. Try again later.
Articles 1–20